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Glycolysis and glyconeogenesis play crucial roles in the ATP supply and synthesis of glycoconjugates, important for the viability
andvirulence, respectively, of thehuman-pathogenicstagesof Trypanosoma brucei, Trypanosoma cruzi, andLeishmania spp. These
pathways are, therefore, candidate targets for antiparasite drugs. The glycolytic/gluconeogenic enzyme enolase is generally highly
conserved,with similaroverall foldandidentical catalyticresidues inallorganisms.Nonetheless, potentially importantdiﬀerences
exist between the trypanosomatid and host enzymes, with three unique, reactive residues close to the active site of the former that
might be exploited for the development of new drugs. In addition, enolase is found both in the secretome and in association with
the surface of Leishmania spp. where it probably functions as plasminogen receptor, playing a role in the parasite’s invasiveness
and virulence, a function possibly also present in the other trypanosomatids. This location and possible function of enolase oﬀer
additional perspectives for both drug discovery and vaccination.
1.Introduction
All known organisms belonging to the Trypanosomatidae,
a family of protists within the order Kinetoplastida, are
parasites of vertebrates, invertebrates, or plants. Species of
two trypanosomatid genera, Trypanosoma and Leishmania,
are responsible for several serious diseases of humans and
domestic animals in the tropical and subtropical regions of
the world [1].
Trypanosoma brucei is the causative agent of human
sleeping sickness, a disease that threatens millions of mainly
impoverished peoplein36countriesoftheAfricancontinent
[2]. This parasite is transmitted by several species of the
genus Glossina, insects commonly known as tsetse ﬂies,
which are endemic in the aﬀected sub-Saharan countries.
The two human infective subspecies of T. brucei, T. b. rhode-
siense,a n dT. b. gambiense, live extracellularly, multiplying
as so-called long-slender trypanosomes in the bloodstream
[3]. By a population-density-dependent mechanism, the
slender trypanosomes may transform into nonproliferative
stumpy bloodstream forms. Trypanosomes are passed on
to the insect vector when a tsetse ﬂy takes blood from an
infected host. Once in the tsetse ﬂy gut, the stumpy parasites
diﬀerentiate into so-called procyclic-form trypanosomes,
which subsequently undergo several successive diﬀerentia-
tions while migrating from the gut via the proboscis to
the salivary glands. From there, the parasites, then called
metacyclic forms, are transmitted to a new host [1, 4].
Without treatment, human sleeping sickness is considered
fatal. Vaccines or adequate drugs for eﬀective treatment of
this disease are currently not available [2].
Trypanosoma cruzi is responsible for Chagas’ disease in
South and Central America, a form of trypanosomiasis that
threatens 15 million people on the American continent. This2 Enzyme Research
parasite is mainly transmitted to humans via the feces of
infectedtriatomine bugs;however,transfusions withinfected
blood,organ transplantations, and use ofcontaminated food
are also important ways of transmission [5]. T. cruzi is an
intracellular parasite of humans and many other vertebrates;
the parasite is dedicated to invade cardiac and digestive
tissues, where infective trypomastigotes diﬀerentiate into
replicative amastigote forms. The amastigotes diﬀerentiate
again into trypomastigotes in the cytosol before they burst
from the infected host cell, thus liberating parasites that per-
form a new round of cell infection. Blood trypomastigotes,
taken up again by triatomine bugs when they feed on an
infectedhost,diﬀerentiatethenintoreplicativeepimastigotes
in the insect’s intestine. A next diﬀerentiation occurs in
the intestine, producing vertebrate infective, metacyclic
trypomastigotes. The parasites are transmitted again to the
vertebrate host when the infected bug takes a blood meal,
depositing the contaminated feces on the skin of the new
host [1]. People infected with T. cruzi can only be eﬀectively
treated when such treatment is applied shortly after the
infection has occurred.
SeveralspeciesofthegenusLeishmania aretheetiological
agents of leishmaniasis, a disease characterized by clinical
manifestations withawiderangeofsymptoms. The diseaseis
distributed in 88 countries of tropical and subtropical areas
around the world. It is estimated that currently 350 million
people are at risk. The parasite is transmitted by the bite of
a female phlebotomine sand ﬂy, which feeds from vertebrate
blood [1].
Leishmaniasis can occur as three diﬀerent forms: cuta-
neous leishmaniasis is the most common and mild form
of the disease characterized by the presence of ulcers that
appear at the places of parasite inoculation; mucocutaneous
leishmaniasis is manifested by destruction of the mucosa
membranes ofmouth, nose, and throat after parasite spread-
ing; visceral leishmaniasis is the most dangerous form of
the disease in which organs such as liver and spleen are
compromised. Leishmania species multiply mainly inside
host macrophages as amastigote forms; this form of the
parasite is present in the phagolysosome where the parasite
divides until they burst from the host cells. Subsequently,the
released amastigotes invade new cells, in that way spreading
the infection. The parasite is taken up by the sand ﬂy
when a female phlebotomine feeds on an infected host. The
amastigotes then diﬀerentiate into proliferative metacyclic
promastigote forms in the sand ﬂy gut before migrating
to the salivary glands in order to be transmitted to a new
host [1]. Cutaneous and mucocutaneous leishmaniases are
disabling diseases that aﬀect the quality of life of infected
people;however, visceral leishmaniasis is a fatal disease when
no treatment is applied.
Although several drugs are available to be used for
sleeping sickness, Chagas’ disease and leishmaniasis, they
do not oﬀer adequate treatment. None has been rationally
designedtospeciﬁcallytreatthesediseases.Asaconsequence,
toxic side eﬀects, sometimes very serious, are associated with
the use of such drugs, and increasing resistance has been
reported against some of them. Additionally, the application
of some of the treatments requires highly qualiﬁed staﬀ
and medical equipment, which are usually not available
in the regions where most of the people aﬀected by these
diseases live [1]. Consequently, there exists an urgent need
to develop new drugs that will inhibit the viability of the
parasites while causing minimal side eﬀects to the infected
people and which can be easily administered and will be
aﬀordable for these people usually living in resource-poor
areas of the world. In that context, eﬀorts have been made in
recent decades to identify, in the parasites, crucial metabolic
pathways or cellular structures with features suﬃciently
diﬀerent from those in the host in order to exploit them as
chemotherapeutic targets.
Several features distinguish members of the Trypanoso-
matidae family from other eukaryotic cells. A unique feature
of all kinetoplastids is that the majority of glycolytic and
gluconeogenic enzymes are compartmentalized in unique
peroxisome-like organelles called glycosomes [6, 7]. Several
lines of evidence have shown that this compartmentaliza-
tion is absolutely essential for survival of the organisms.
Metabolic studies on T. brucei, T. cruzi,a n dLeishmania
spp. have shown that in the human-pathogenic stages of
each of these parasites glycolysis and/or gluconeogenesis are
crucial—or at least major processes in the provision of free
energy and carbon—and consequently essential for parasite
viability. Moreover, the peculiar compartmentalization of
these pathways in kinetoplastids has endowed the enzymes
with speciﬁc structural and functional properties that oﬀer
potential for development of trypanocidal drugs [8].
Trypanosomatid parasites are also equipped with several
potent mechanisms that allow them to evade the immune
response by the host, as well as to migrate through several
tissue barriers to reach their ﬁnal destination. T. brucei
is present in the bloodstream of the mammalian host
during the initial phase of the infection. A sophisticated
mechanism of antigenic variation at the level of their
surface coat allows the parasites to escape continuously
from the host’s immune defense system [4]. At a second
stage of the disease, the parasites reach the central nervous
system by crossing the blood-brain barrier via a multistep
mechanism of which the details remain to be established [9].
In contrast, T. cruzi lives only brieﬂy in the bloodstream
of the vertebrate host before invading the cardiac muscle
and cells of the digestive system. It is known that metacyclic
trypomastigotes initially adhere to the host cell through
several proteins exposed on the parasites’ cell surface that
function as ligands and adhering molecules. Then, the
parasites control their invasion by exploiting phagocytic and
nonphagocytic mechanisms that lead to their internalization
into the parasitophorous vacuole. Once there, the parasites
diﬀerentiate into amastigotes, which excrete potent pore-
forming peptides and transsialidases/neuraminidases that
mediate the vacuolar membrane’s disintegration to let the
parasites free in the cytosol in order to multiply [10].
Metacyclic promastigotes of Leishmania spp. are exposed
during a very short time to the lytic factors present in
the bloodstream. Surviving parasites are able to adhere
throughdiﬀerentmechanisms to thehost cell, which belongs
to the monocyte/macrophage family. The presence on the
parasites’ surface of lipophosphoglycans, metalloproteases,Enzyme Research 3
and speciﬁc ligands for macrophage receptors allows the
p a r a s i t e st oi n v a d et h eh o s tc e l l s ,a sw e l la sm i g r a t et h r o u g h
the extracellular matrix [11]. Once in the phagolysosome,
promastigotes diﬀerentiate into amastigotes that are better
equipped with molecules that provide resistance against the
stress conditions encountered in the phagolysosome, such as
t h ep r e s e n c eo fh y d r o l a s e sa n dt h ea c i d i cp H .T h es u r f a c e
molecules of the amastigotes play an important role in
inhibiting the mechanism that triggers the macrophage’s
activation as well as the proper antigen presentation through
theMHCIandII complexes,which eventuallywouldactivate
ah o s tp r o t e c t i v eT H1-cell response [12].
Studies of the metabolic pathways essential for parasite
survival and the mechanisms by which the trypanosomatids
establish an infection in the human host are important
both for future chemotherapy and vaccination. Such studies
may identify molecules—unique or at least highly diﬀerent
from host molecules—that are interesting as candidate drug
targets and the subsequent discovery of selective inhibitors
of these molecules to combat the parasitic diseases, as well
as molecules that could be exploited as potential antigens to
induce immunoprotection against the trypanosomiases and
leishmaniases.
In this paper, we will argue that enolase, a protein
involved both as enzyme in glycolysis and gluconeogenesis,
metabolic processes essential for T. brucei, T. cruzi,a n d
Leishmania spp.,andprobablyalsoasavirulencefactorinthe
pathogenesiscausedbyLeishmania spp.,T. cruzi andpossibly
also T. brucei, represents both an interesting drug target and
vaccine candidate.
2.GeneralAspectsof Enolase
Enolase is the enzyme responsible for the reversible con-
version of D-2-phosphoglycerate (2PGA) and phospho-
enolpyruvate (PEP) in glycolysis and gluconeogenesis, two
metabolic pathways that are often vital for cellular function
[13]. Enolase is a highly conservedprotein found in Archaea,
Bacteria, and eukaryotes with catalytic properties that are
similaramongdivergentorganisms. Theubiquitouspresence
of the enzyme and the sequence homology between enolases
from extant organisms belonging to diﬀerent phyla indicate
thatan enolase gene hasalready beenpresent in thecommon
ancestor and diversiﬁed by speciation of organisms and gene
duplication within organisms [14].
Since enolase catalyzesthe reversible conversion of2PGA
into PEP, the forward reaction being the ninth step of
glycolysis and the reverse reaction being the ﬁrst one of
gluconeogenesis, an organism, tissue, or cell may need to
optimize the properties of this enzyme in such a way that
the ﬂux in either one or the other direction is facilitated,
dependent on whether it should adapt its metabolism to
performing the catabolic or anabolic process. Indeed, in
manyorganisms (vertebrates,Saccharomycescerevisiae, Toxo-
plasma gondii) the presence of diﬀerent enolase isoforms has
been reported, often with kinetic properties favouring a ﬂux
in the glycolytic or gluconeogenic direction. In vertebrates,
it has been shown that expression of the diﬀerent enolase
isoforms, formed by homodimers and heterodimers of α,
β,a n dγ subunits, is regulated in a developmentally and/or
tissue-speciﬁc manner [13, 15]. In yeast, the expression
of the two enolase isoforms is dependent on the carbon
source used topropagatethecells, glucose,oranonglycolytic
substrate; however, the kinetic properties of homodimeric
e n z y m e so fb o t hi s o f o r m sa r ev e r ys i m i l a r[ 16]. In the case
of T. gondii, the speciﬁc expression of enolase genes is linked
to life-stage conversion. While enolase 1 is expressed during
encystations where anaerobic glycolysis is promoted, enolase
2 is expressed in the actively dividing and invasive tachyzoite
[17].
Some highly conserved proteins perform multiple func-
tions that are diﬀerent from their “classical”, well-known
activities, and, therefore, are called “moonlighting” func-
tions. These latter functions are often revealed when these
proteins are found at cellular localizations diﬀerent from
where the primary function is exerted. A considerable
number of glycolytic enzymes, including enolase, exhibit
nonglycolytic functions in several organisms, both bacteria
and eukaryotes. Enolase is located mainly in the cytosol of
all eukaryotic cells where, besides its function in glycolysis
and gluconeogenesis, it is also involved in regulation of cell
morphology and material traﬃcking by interacting with the
cytoskeleton system [18]. Enolase has also been detected in
the nucleus of mammalian cells where it participates in tran-
scriptional regulation of genes involved in morphological
transformation and cell proliferation [19]. Bacterial enolase
has been reported as a main component of the degradosome
where it functions, in a still poorly understood manner, in
the regulation of mRNA stability [20]. The mammalian α-
enolase is also found as a main structural component of the
eye lens, where it is found as an inactive monomer [13].
Additionally, a considerable number of reports described
that enolase can be expressed at the cell surface of several
nonpathogenic and pathogenic organisms. The enzyme has
been found at the cell wall of S. cerevisiae and also at the
surface of the pathogenic yeast Candida albicans where it
constitutes an immunodominant antigen during invasive
candidiasis [21]. In some bacterial pathogens, such as Bacil-
lus anthracis, Streptococcus pneumoniae, and Streptococcus
mutans [22–24], surface enolase has been highlighted as
an important virulence factor. In Apicomplexan parasites
like Plasmodium spp. [25], cell surface enolase has been
suggested to participate in the tissue invasion process.
Additionally, in Entamoeba invadens, enolase expression is
induced by environmental signals, and it shows association
with cytoplasmic vesicle-like structures that transport the
protein to the cyst wall where it plays an essential but so far
unknown function [26]. Human and animal parasites of the
genus Schistosomahave beenreported to express enolase also
on the surface of the adult worms [27, 28], where it could
exert an important role in the inhibition of clot formation
during host infection [28].
Enolase may also be excreted to the extracellular envi-
ronment where it mediates degradation of host tissues and
immune evasion, such as has been observed for the human
pathogenic Streptococcus pyogenes and the insect parasite
Aphidius ervi [29, 30].4 Enzyme Research
3.Enolaseof Trypanosomatids
African trypanosomes living in their mammalian host are
entirely dependent on glucose, abundantly available in the
blood. Metabolic studies performed on bloodstream-form T.
brucei have shown that glycolysis represents the only process
through which ATP is synthesized by the parasite. Inhibition
ofglycolysis,therefore,leadstorapiddeathoftheseparasites.
Thesameispr obablytrueforthehumanpathogenicstagesof
T. cruzi. Axenically cultured amastigotes have an essentially
glycolytic metabolism, fermenting glucose to succinate and
acetate [32], strongly suggesting that also in these cells eno-
lase might be a candidate drug target. Glycolysis is probably
also essential in the trypomastigote form of these parasites,
as it lives in a glucose-rich bloodstream where it shows a
highlyupregulatedglucoseuptakeactivity[33].Interestingly,
the pathogenic stage of Leishmania, the amastigotes living
intracellularly in phagolysosomes of macrophages, utilize
amino sugars as a source of carbon and energy, indicating
that glycolysis is important [34], while even during hexose
uptake gluconeogenesis has been shown to be an essential
pathway for the synthesis of glycoconjugates and β-mannan,
both required for the virulence of the parasite [35, 36];
therefore, enolase could also be considered as vital, and
thus a drug target, in this organism. The fact that even
during uptake of (amino) sugars gluconeogenesisis required
has been interpreted as an indication that the sugar levels
in the phagolysosome are generally too low to sustain
ﬂuxes through essential pathways such as N-glycosylation,
the pentose-phosphate pathway, inositol synthesis, and the
catabolism of major carbohydrate reserve material [34].
In these three parasitic trypanosomatid species, as in
all kinetoplastids, the majority of the glycolytic enzymes—
dependent on the life-cycle stage, the 6 or 7 enzymes from
hexokinase to glyceraldehyde-3-phosphate dehydrogenase
or phosphoglycerate kinase, converting glucose into 1,3-
bisphosphoglycerate or 3-phosphoglycerate, respectively—
are compartmentalized in peroxisome-like organelles called
glycosomes [6, 37, 38]. Only the last enzymes of the
pathway—phosphoglycerate mutase, enolase, and pyru-
vate kinase—were not found to be associated with these
organelles. More detailed studies speciﬁcally devoted to
enolase have conﬁrmed that its activity is exclusively present
in the cytosol of T. brucei bloodstream forms [39], T. cruzi
epimastigotes (W. Qui˜ nones, and J. L. Concepci´ on, unpub-
lished results), and L. mexicana promastigotes [40]. In T.
cruzi, the enzyme was detected by peptide mass ﬁnger-
printing in the diﬀerent developmental stages with a higher
expression in trypomastigotes and amastigotes compared to
epimastigotes [41]. In contrast, mass-spectrometric analysis
of diﬀerentiating L. mexicana showed that the glycosomal
glycolytic enzymes were 1.4-fold upregulated during axenic
diﬀerentiation of promastigotes to amastigotes whereas the
cytosolic glycolytic enzymes including enolase were 2-fold
downregulated [42].
In bloodstream-form T. brucei, enolase has been geneti-
cally validated as a drug target by RNA interference (RNAi)
[43]. Upon induction of RNAi, enolase activity gradually
decreased during the ﬁrst 24h to 16%, leading to growth
arrest followed by trypanosome death after two days.
The genes coding for enolases of T. brucei, T. cruzi,
L. mexicana, and L. major have been identiﬁed in the
genomesequencedatabase(TriTrypDB:http://tritrypdb.org/
tritrypdb/) for a variety of African trypanosomes (T. brucei,
T. gambiense, T. congolense, T. vivax), the American try-
panosome T. cruzi, and several Leishmania species (L. major,
L.mexicana,L.infantum,L.braziliensis). Ineachcase,asingle
gene copy per haploid genome has been found, except in
T. gambiense where two tandemly linked genes coding for
identical proteins were found, clearly the result of a recent
geneduplicationinthisspecies.Theyallencodepolypeptides
of 429 amino acids (including the initiator methionine) with
relative molecular masses of 46kDa. Only the predicted T.
congolense enolase polypeptide has 430 residues due to the
presence of an additional Lys residue at the C-terminus. The
Trypanosoma amino-acid sequences show approximately
80% identity with the Leishmania sequences. Comparison
of the three isoenzymes of the parasite’s human host
and trypanosomatid enolases reveals between 60 and 63%
identity. Residues essential for substrate binding, catalytic
activity, as well as those constituting the binding sites of
substrates, and two Mg2+ ions are invariably present in all
sequences (see the multiple sequence alignment in Figure 1).
The protein has been more extensively studied in T.
brucei and L. mexicana [39, 40, 44]. Both enzymes have been
puriﬁed from the parasites and expressed as N-terminally
His-taggedproteinsinEscherichia coli.T h ek i n e t i cp r o p e rt i e s
of both the natural and bacterially expressed enzymes were
determined for the forward (glycolytic) and reverse (glu-
coneogenic) reactions. In each case, the enzyme displayed
standard Michaelis-Menten kinetics for both substrates with
very similar Km and Vmax values (Table 1). Mg2+ is essential
for the activity of all enolases (with Ka values varying
between 0.26 and 0.45mM; optimal concentration for activ-
ity between 1 and 2mM), from trypanosomatids and other
organisms, but inhibits the enzymes at high concentrations.
The K
app
i values of the trypanosomatid and yeast enzymes
for Mg2+ are similar (43–50mM), but the mammalian
enzyme is more susceptible to inhibition; the inhibition of
this latter enzyme, but not that of trypanosomatids and
yeast, is pH dependent and seems to involve two processes
with K
app
i values of 7.5 (40% inhibition) and >100mM.
Furthermore, other divalent metals such as Co2+,M n 2+,a n d
Cu2+ inhibit all enolases tested. Enolases are also generally
inhibited by the monovalent ions Li+ and Na+; rabbit muscle
enolase is activated by K+, but the trypanosomatid and
yeast enzymes are not. Furthermore, theL. mexicana enzyme
is inhibited by ﬂuoride with Ki values of 1.9mM (versus
2PGA) and 6.3mM (versus PEP) for the natural enzyme
and 13.0mM (versus 2PGA) and 10.0mM (versus PEP) for
the bacterially expressed enzyme, in agreement with reports
aboutotherenolases. Similarly,enolase puriﬁedfrom T. cruzi
epimastigotes is inhibited by ﬂuoride with a Ki value of
2.6mM (versus 2PGA; L. Gonz´ alez-Gonz´ alez, W. Qui˜ nones,
and J. L. Concepci´ on, unpublished results). The L. mexicana
enolase is also inhibited by inorganic pyrophosphate (PPi):
Ki = 0.232mM (versus 2PGA) and 0.238mM (versus PEP)Enzyme Research 5
MTIQK - VHGREVLDSRGNPTVEVEVTTERGVF - RSAVPSGASTGVYEACELRDGDKKRYVGKGCLQAVKNVNEVIGPALIGR--DELKQEEL
MTIQK - VHGREI LDSRGNPTVEVEVTTELGVF - RSAVPSGASTGIHEACELRDDDKRRYLGKGCLNAVKNVNDVLAPALVGK--DELQQSTL
MP I LK - IHAREVLDSRGNPTVEVELTTEAGVF - RSAVPSGASTGVHEACELRDGDKARYCGAGCTQAVKYVNE ILAPA L V G K--DESD QAGL
MS I LK - IHAREI FDSRGNPTVEVDL FTSKGLF- RAAVPSGASTGIYEALELRDNDKTRYMGKGVSKAVEHINKTIAPALVSKKLNVTEQEK I
MS I IT DVYAREVLDSRGNPTLEVEVYTESGAFGRGMVPSGASTGEHEAVELRDGDK SRYGGLGTQKAVDNVNNIIA EAIIGY--DVRDQQA I
T. brucei:
T. cruzi:
L. mexicana:
S. pneumoniae:
∗ 20 ∗ 40 ∗ 60 ∗ 80 ∗
:8 8
:8 8
:8 8
:9 0
:9 0
Human:
(a)
DTLMLRLD G TPNKGKLGANAILGCSMAI SKAAAAAKGVPLYRYLAS LAGTKEL RLPVPCFNVINGGKHAGNA LP FQEFMIAPVKATSFSEAL
DKLMRDLD G TPNKSKLGANAILGCSMAI SKAAAARKGVPLYRYLAELAGTKEVRLPVPCFNVINGGKHAGNA LP FQEFMIAPVKAGSFNEAL
DKLMCELD G TKNKSKLGANAILGCSMAI SKAAAAKAGVPLYRY IAGLAGTKDMRLPVPCFNVINGGKHAGNVLP FQEFMIAPTKATSFREAL
DKLMIEMDGTENKSKFGANAI LGVSLAVCKAGAVEKGVPLYRHIA DLAGNSEV I LPVPAFNVINGGSHAGNK LAMQEFMI LPVGAANFREAM
DRAMIALD G TPNKGKLGANAILGVSIA V ARAAADYLE IPLYS YLG---GFNTKVLPTPMMNIINGGSHSDAP IAFQEFMILPVGAPTFKEAL
T. brucei:
T. cruzi:
L. mexicana:
S. pneumoniae:
100 120 ∗ 140 ∗ 160 ∗ 180 ∗
: 180
: 180
: 180
: 182
: 179
Human:
(b)
RMGS EVYHS LRGIIKKKYGQDAVNVGDEGGFAP P I KDINEPLP IL M EAIEE AGHRG- - KFAI CMDCAASET YDEKKQQYNL TFKS PE--PT W
RMGAEVYHS LKS IIKKKYGQDAVNVGDEGGFAP P I TDINEPLP IL M EAIEQAGHKG- - RFAI CMDSAASET YDENKKQYNL TFKS PE--AT W
RMGS EVYHALKGIIKGKYGQDAVNVGDEGGFAP P I KQIDEPLP IL M EAIEKAGHKG- - KFAI CMDCAASEAYDAERKMYNL TFKNPE--PTY
RIG AEVYHNLKNVIKEKYGKDATNVGDEGGFAPNI LENKEGLELLKTAIGKAGYTD-- KVV I GMDVAASEF FRSGK --YDLDFKS PDDP S R Y
R YGAEIFH ALKK ILKSR - GLETA-VGDEGGFAPRFEGTEDGVETILAAIEAAGYVPGKDVF I GFDCAS SEF YDKERKVYDY TKFEGEG-AAV
T. brucei:
T. cruzi:
L. mexicana:
S. pneumoniae:
200 ∗ 220 ∗ 240 ∗ 260 ∗ ∗
: 268
: 268
: 268
: 270
: 268
Human:
(c)
VTAEQLRETYCKWAHDYPIVSIEDPYDQDDFAGFAG ITEALKGKTQIVGDDLTVTNTERIKMAIEKKACNSLLLKI NQIGTI SEAI ASSKLC
VTAKQLAETYAKWVSEYPIVSLEDPYDQDDFDG FAG ITEALKGKAQVVGDDLTVTNVSRIKTAIEKKACNSLLLKI NQIGTITEAI EASK FC
VSAAKLQETYERWVSEYPLVSIEDPFAEDNFDE F SAITKALAGKAQIVGDDLTVTNVERVKMAIDKSACNSLLLKI NQIGTI SE S I AAAKLC
ISPDQLADLYKSFIKDYPVVSIEDPFDQDD WGAWQKFTASAG--IQVVGDDLTVTNPKRIAKAVNEKSCNCLLLKVNQIGSVTESLQACKLA
RTSAEQIDYLEELVNKYPI ITIEDGMDENDWDGWKALTERLGKKVQLVGDDFFVTNTDYLARGI QEGAANS IL I KVNQIGTLTETFEA IEMA
T. brucei:
T. cruzi:
L. mexicana:
S. pneumoniae:
280 300 ∗ 320 ∗ 340 ∗ 360 ∗
: 360
: 360
: 360
: 360
: 360
Human:
(d)
MENGWSVMVSHRSGETEDTY IADLVVALGSGQIKTGAPCRGERTAKLNQLL R I E EE LGAHAKFGFPGWS-----
MSNGWSVMVSHRSGETEDTY IADLVVGLGTGQIKTGAPCRGERTAKLNQLL R I E EE LGAHAKFGFPAWS-----
MENGWSVMVSHRSGETEDTY IADL SVGLGTGQIKTGAPCRGERTAKLNQLL R I E EEMGSAAKYGYPGWA---- -
QANGWGVMVSHRSGETEDTF IADLVVGLCTGQIKTGAPCRSERLAKYNQLL R I E EE LGSKAKFAGRN F RNPLAK
KEAGYTAVVSHRSGETEDST IADIAVATNAGQI KTG SLSRTDR I AKYNQLL R I EDQLGEVAEYRGLK S FYNLKK
T. brucei:
T. cruzi:
L. mexicana:
S. pneumoniae:
380 ∗ ∗ 400 ∗ 420 ∗ 440
: 429
: 429
: 429
: 434
: 434
Human:
(e)
Figure 1: Characteristics of the enolasesequences of trypanosomatids. Alignmentof the amino-acid sequences of enolase from L. mexicana
(accession number ABA64522), T. brucei (accession number XP 822542), T. cruzi (accession number XP 819700), human α-enolase
(accession number NP 001419), and S. pneumoniae (accession number Q97QS2). Open circles indicate residues involved in ligand binding
(PEP, metals), closed circles unique reactive active-site residues found in enolases of trypanosomatids. The bar indicates the plasminogen-
binding motif in S. pneumoniae. This plasminogen-binding peptide contains both positively and negatively charged residues ﬂanked by
hydrophobic amino acids, important for plasminogen binding [31].
for the natural enzyme and Ki = 0.127mM (versus 2PGA)
and 0.260mM (versus PEP) for the recombinant enzyme.
For the natural T. cruzi enzyme, inhibition by PPi with a
Ki = 0.21mM (versus 2PGA) was found (L. Gonz´ alez-
Gonz´ alez, W. Qui˜ nones, and J. L. Concepci´ on, unpublished
results). The susceptibility of T. brucei enolase to PPi has not
been tested. It should be noted that, previously, several other
Leishmania and T. cruzi glycolytic enzymes have been shown
to be inhibited by PPi [45, 46] whereas no such inhibition
was found for T. brucei enzymes.
4.EnolaseThree-Dimensional
Structure:UniqueFeaturesof
the TrypanosomatidEnzyme
Crystal structures of enolase—the enzyme in its apo-form
and with bound ligands—are available for a variety of
organisms: S. cerevisiae, lobster, and E. coli. The structural
analysisofthesediﬀerentenolaseshasshownthattheenzyme
usually folds as a homodimer, although, for enolase of
some bacteria, an octameric quaternary structure has been
reported. The overall structure and catalytic site are highly
conserved, explaining the very similar kinetic properties
between the enzymes from highly diﬀerent organisms, as
described in the previous section. Each subunit of the dimer
is composed of two domains, a small N-terminal domain
containing three αhelices and four β sheets and aC-terminal
domain which folds as an atypicaleight-fold α/β barrel at the
end of which the active site is found. Although the catalytic
site lies at the dimer interface, each site involves residues of
only a single subunit, explaining that the monomeric form is
catalyticallyactive,despiteearlierclaimsofthecontrary [47].
The early studies, particularly with the yeast enzyme, had
shown that the enzyme is naturally activated by two divalent6 Enzyme Research
Table 1: Kinetic characteristics of the natural and recombinant
enolases of T. brucei, T. cruzi,a n dL. mexicana.
Source of enzyme
Km Vmax
(μM) (μmol·min−1·mg−1)
2PGA PEP 2PGA PEP
T. brucei (natural) 54 244 ND ND
T. brucei (recombinant) 49 289 63 6.3
T. cruzi (natural) 55 147 97 42
T. cruzi (recombinant) 50 410 0.87 12.35
L. mexicana (natural) 80 216 16.0 3.38
L. mexicana (recombinant) 51 200 80.0 3.64
Rabbit muscle 16 238 31 6.4
Yeast 57 264 65 7.8
Data of T. brucei, rabbit muscle, and yeast enolases were taken from
Hannaertet al.[39],thoseofL.mexicanaenolasesfromQui˜ nonesetal. [40],
and the T. cruzi data have not yet been reported before (L. Gonz´ alez-
Gonz´ a l e z ,W .Q u i ˜ nones, and J. L. Concepci´ on, unpublished results).
Abbreviations: 2PGA: D-2-phosphoglycerate; PEP: phosphoenolpyruvate;
ND: not determined.
metal ions that bind to each monomer in two distinct metal-
binding sites (I and II) near the active site. These studies also
revealed the importance of sequential binding of a ﬁrst metal
ion, the substrate and a second metal ion, and associated
local conformational changes, notably movements of three
loops near the active site, for catalysis to occur. The loops
deﬁne “open,” “closed,” and “incompletely closed” active-
site structures [48]. Structures of the apo-enzyme and the
enzyme in complex with its substrate or product indicate
that, in the “open” conformation, the active site is totally
exposed to solvent. When the substrate or product and
the divalent ions are bound, an important conformational
change occurs, bringing the loops one (comprising residues
37–44), two (150–166), and three (248–272) to the catalytic
active site producing the “closed” enzyme conformation
[48]. The catalytic mechanism of the reaction implies an
acid-base chemistry involving a Lys-Glu dyad.
It had also already initially been found that enolase
activity is inhibited by high metal concentrations, which
suggested the presence of a third inhibitory metal binding
site. Notwithstanding the agreement about the kinetic data,
no structural data were available to support this hypothesis.
More recently,sevenstructural determinationshavebeen
performed for the T. brucei enzyme in ligation states with
substrates, inhibitors, sulphate, phosphate, and metal ions–
and in various conformations [49, 50]. A subunit structure
of T. brucei enolase is shown in Figure 2. All these structures
togetherhaveprovidedaprofoundinsight intothestructure-
function relationship and the catalytic mechanism of the
enzyme, and they solved some questions raised by the earlier
structure determinations.
First, the diﬀerent structures of the T. brucei enzyme and
complementary molecular dynamics simulations revealed a
strikingly larger conformational variability for the catalytic
loops than initially thought. Secondly, in the studies of the
parasite’s enzyme, also an unexpected diversity of metal
binding was found, and two additional metal-binding sites
Figure 2: Cartoon view of T. brucei enolase in complex with the
enolase inhibitor phosphonoacetohydroxamate (PAH; PDB code
2ptz [50]). Secondary structure is coloured blue (α-helices), green
(β-strands) or purple (loops) with the N-terminal domain to the
right of the ﬁgure drawn in darker hues. Ligand is shown as sticks
and bound metals as isolated spheres. The putative plasminogen-
binding site is shown in orange.
were detected near the active site. The occupancy of one of
these sites, site no.III, explained theinhibitory eﬀectofMg2+
at high concentrations; the contribution of site IV to this
inhibition remains to be determined.
Importantly, all available structures together, from try-
panosomesandotherorganisms, andasequencecomparison
of trypanosomatid and human enolases have revealed that,
despite the high similarity (approximately 60% positional
amino-acid identity), similar overall fold and active-site
architecture and identical catalytic residues, potentially
important diﬀerences exist between parasite and host
enzymes that might be exploited for drug discovery. First,
each of the trypanosomatid enolases contains three unique
residues, absent from the enolases of mammals and almost
all other organisms studied (Figure 1), which might be
targets for irreversible reaction with active-site inhibitors
[39]. A pair of cysteine residues, numbered 147 and 241
(see Figure 3), is present in a water-ﬁlled cavity near the
active site. Despite their proximity, no disulphide bond
between these residues was observed in the structure, nor
is expected to be formed in vivo because of the low redox
potential in the cytosol. One of these residues, and probably
both, could be chemically modiﬁed by iodoacetamide with
concomitant loss of enzyme activity indicating their accessi-
bilityto potentially reactive ligands [49].Substrate analogues
extended with reactive groups reaching either one of these
Cys residues underneath the catalytic site may thus result in
trypanosomatid-enzyme speciﬁc, irreversible inhibitors. In
addition, a unique Lys, at position 155, was located on one
of the active-site loops (Figure 3) and could also potentially
interact with ligands in the active site. Although the side
chain of this Lys residue points away from the catalyticsite in
original T. brucei enolase crystal structures, later structures,
backed up by molecular dynamics simulations, show the LysEnzyme Research 7
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Figure 3: Close-up view of the catalytic site and neighbourhood
of T. brucei enolase in complex with the inhibitor phosphonoace-
tohydroxomate (PAH) (PDB code 2ptz) [50]. Ligand is shown in
ball and stick representation and bound metal as grey spheres.
Bound water molecules near the Cys residues are shown as lime
green spheres. Selected secondary structure is shown as magenta
(β-strands) or pink (loops). Selected residues are shown as sticks
and labeled with those discussed in the text as potentially relevant
to trypanosomatid-speciﬁc drug design coloured white.
to approach the catalytic site more closely; it may, therefore,
be available for irreversible binding of active-site inhibitors.
Despite the closed catalytic site being small, the studies
showed that occupation of the site by ligands does not need
to lead to full closure, leaving open a tunnel near which Lys
155 is closely located. This oﬀers thus a possibility for the
design of enlarged ligands that interact with this potentially
modiﬁable residue and inhibit the enzyme irreversibly.
5.Plasma-Membrane Bound and Secreted
EnolaseinLeishmania Parasites
A study of enolase localization in L. mexicana by dif-
ferential centrifugation detected this protein, as expected
from its function in glycolysis/gluconeogenesis, mainly in
the cytosol. However, some enolase was also present in
the microsomal fraction that contains predominantly the
plasma membrane [40]. Similar results were obtained upon
selective permeabilization of cells with digitonin; Western
blot analysis showed that enolase was present in both the
supernatant and pellet of each cell suspension, independent
of the digitonin concentration added, indicating that the
detergent was unable to fully release the enzyme from the
permeabilized cells. These results suggested that enolase
might be associated with membrane constituents of the
cell. The presence of enolase at the plasma membrane
was further assessed by immunoﬂuorescence experiments
using nonpermeabilized parasites [40]. These experiments
not only conﬁrmed the plasma-membrane localization of
enolase but also showed that it is associated to the external
surface of the parasite. In agreement with these results is
the recent visualization of enolase in the proteome of the
plasma membrane fromLeishmania chagasi, prepared by two
diﬀerentapproaches: livecellbiotinylationfollowedbystrep-
tavidin aﬃnity puriﬁcation and octyl glucoside extraction
[51]. Prior to these studies, subcellular fractionation of L.
infantum with digitonin followed by proteomic analysis of
the diﬀerent fractions had predicted that enolase could have
an additional localization, apart from the cytosol, also in this
species [52].
Measurement of the enolase activity in the fractions
obtained by diﬀerential centrifugation of an L. mexicana
lysate showed that it was all present in the cytosolic
fraction; noactivity whatsoeverwasfoundinthemicrosomal
fraction [40], indicating that the enolase on the parasite
surface is inactive. This was corroborated by the digitonin
solubilization experiment: all enolase activity was released
with the cytosolic marker and no activity was detected in
the pellets [40]. Another indication for the lack of activity
of this surface enolase was recently provided by the report
that its localization in L. donovani and L. major is regulated
by oligopeptidase B (OPB), a serine-protease that is highly
expressed in the amastigote form [53]. Although loss of this
peptidase in OPB−/− parasites resulted in the accumulation
of enolase at the cell surface of the parasites, no increased
enolase activity was detected in total cell lysates. The authors
hypothesized that oligopeptidase B causes clearance of sur-
face enolase, once in the macrophage, to avoid macrophage
activation [53]. This hypothesis is consistent with enolase
having multiple functions.
Enolase is also present at the cell surface of several
mammalian cells [54–56]. In addition, enolase can be
found at the cell surface of numerous prokaryotic and
eukaryotic pathogenic organisms including, among others,
group A streptococci [57], S. pneumoniae [58], L. mexicana
[40, 53, 59], C. albicans [60], Schistosoma bovis [61], and
Plasmodium falciparum [25]. In the majority of these
cases, enolase could act as a plasminogen-binding protein.
Plasminogen is the zymogenic form of the serine-protease
plasmin that is part of the ﬁbrinolytic system. This molecule
possesses ﬁve kringle domains that provide lysine-binding
sites responsible for its binding to protein substrates and cell
surfaces [62]. Surface-located enolases of mammalian cells
andsomepathogensbindplasminogenthroughaC-terminal
lysine that is recognized by the lysine-binding sites of the
plasminogen molecule [63]. However, in the amino-acid
sequence of enolase from S. pneumoniae, an internal motif
(FYDKERKVYD) was identiﬁed as being responsible for the
plasminogen recognition [23]. Similar internal motifs were
identiﬁed in the enolases of L. mexicana (AYDAERKMY)
and Aeromonas hydrophila (FYDAEKKEY) [59, 64]. None
of these two latter enolases possesses a C-terminal lysine
residue.Enolases fromothertrypanosomatids (Figures1and
2) as well as from other pathogenic organisms have similar
internal motifs at the same position that could contribute to
plasminogen binding [65]. A similar motif has been shown8 Enzyme Research
to be responsible for plasminogen binding by another L.
protein, the parasite’s homologue of receptors for activated
C-kinase [66].
In addition to its localization on the membrane surface,
enolase is secreted by several pathogenic microorganisms,
such as the bacteria S. pyogenes [30], S. mutans [24], and
Lactobacillus crispatus [67]. In Leishmania parasites, enolase
has been found as a part of the secretome/exosome of L.
donovani [68, 69], L. major [69], and L. braziliensis [70].
Enolase has also been found in the secretome of T. brucei
[71, 72] and as a protein secreted by other parasites: Eimeria
tenella [73], Fasciola hepatica [74], Echinostoma caproni
[75], Giardia lamblia [76], and Schistosoma japonicum [77].
Diﬀerent exosome proteomes from mammalian cell types
indicate that enolase is commonly present in this structure
[78].
Enolase does not contain a detectable secretion signal
or membrane anchor region that can explain its membrane
localization. Studies with S. pneumonia showed that soluble
enolase can bind to the pneumococcal surface, suggesting
that one possibility for the surface localization of enolase in
this bacterium is the reassociation of secreted enolase with
t h ep l a s m am e m b r a n e[ 58]. One may thus speculate that, in
t h ec a s eo fLeishmania parasites, enolase, after its secretion
via exosomes, might bind to the cell surface. Further studies
are necessary to elucidate the mechanism of translocation of
enolase to the cell surface in these parasites.
6.The RoleofPlasminogen/Plasmin
and Enolaseinthe Virulenceof
Leishmania Parasites
The binding of plasminogen to the cell surface has been
demonstrated for severalmammalian cells [54, 63]including
metastatic tumor cells. Equally, over the last 15 years, a
steadily increasing number of reports have been published
aboutplasminogen binding by both prokaryotic and eukary-
otic pathogens, and even viruses [79]. This interaction has
been implicated as part of their mechanisms of invasion
and establishment in the host. However, in contrast to
the large number of reports about plasminogen binding
by mammalian cells and unicellular organisms, only few
analyses have been reported thus far that provide evidence
for the importance and physiological role of this interaction.
Evidence for the physiological role and importance in
infection and pathogenesis of the plasminogen-pathogen
interaction has been provided by studies of animal models
infected with group A streptococci [80], Yersinia pestis
[81], Borrelia spp. [82–84], and S. pneumoniae [23]. The
binding of plasminogen through their plasminogen-binding
proteins and its activation made the pathogens acquire a
potent protease for their own purpose by kidnapping the
ﬁbrinolytic system of the host. Plasmin is involved in several
physiological processes, such as the degradation of ﬁbrin
and other extracellular matrix proteins. Acquisition of this
host protease allows thepathogenstoinvade anddisseminate
in the host. In the case of the streptococci, Staphylococcus
aureus, and Y. pestis, the conversion of plasminogen to
plasmin is achieved by their own plasminogen activators
[85]. The bound plasminogen can also be activated by the
host plasminogen activators, the tissue plasminogen activa-
tor (t-PA), and urokinase (u-PA). Once the plasminogen is
activated, the surface-bound plasmin cannot be inhibited
by the host plasmin inhibitors (for reviews on bacteria-
plasminogen interaction see [30, 85–89]).
Besides L. mexicana, surface plasminogen binding has
also been demonstrated in several other parasites: T. cruzi
[90], Trichomonas vaginalis [91], S. bovis [28, 61], and S.
japonicum [27]. In most of them, enolase has been proposed
as the plasminogen receptor. For L. mexicana, it was
demonstrated that plasminogen and plasmin bind to both
the promastigote and amastigote forms of this parasite [92,
93]. The Kd for this interaction in promastigotes is 2.4μM
for plasminogen and 1.2μM for plasmin. These values are
consistent with an in vivo interaction since the concentration
of plasminogen in plasma and the extracellular milieu is
around 2μM[ 94]. Moreover, enolase seems to contribute
for 60% to this binding, suggesting that it is the principal
plasminogen receptor on the cell surface [59]. This parasite
does not appear to have its own plasminogen activator,
thus requiring an exogenous source of activators similar
to several other plasminogen-binding pathogens such as
Borrelia burgdorferi [95] .t - P A ,u r o k i n a s e ,a n ds t r e p t o k i n a s e
are able to activate the bound plasminogen of L. mexicana.
Indeed, the activation of plasminogen by t-PA is facilitated
in the presence of the parasite (up to nine-fold enhancement
of this activation was observed) [92]. Interestingly, there
are diﬀerent plasminogen-binding capacities among the
morphotypes present in axenic cultures of L. mexicana
promastigotes. Round forms bind more plasminogen than
the slender forms. The proportion of the former is higher in
heat-shocked and aged cultures [93].
Although the role of the interaction with plasminogen
is considered to be important in bacterial pathogenesis,
it is not clear what the function of this interaction is in
the case of Leishmania parasites, particularly because this
organism thrives within macrophages. However,this parasite
can ﬁnd plasminogen, as promastigotes, at the moment
of host inoculation or as amastigotes when it is liberated
from a macrophage to infect other cells. A clue about a
possible function of the interaction of Leishmania with
plasminogen was provided by studies of cutaneous lesions
caused by L. mexicana in plasminogen-deﬁcient mice [96].
In the lesion of plg−/−, mice, the parasites were limited to
isolated foci in contrast to the plg+/+ mice lesion where
a scattered pattern was observed. The parasites were less
infectious in the plasminogen-deﬁcient mice. In the lesion
of plg−/−, increased deposits of ﬁbrin could be observed.
These deposits are present in some organs in plasminogen-
deﬁcient mice [97, 98]. Thus, in natural conditions, ﬁbrin
could be limiting the encounter between Leishmania and
macrophages. Fibrin is part of the host defense mechanism
providing a barrier limiting invasion and dissemination and
is also linked to inﬂammatory response [81, 99]. In addition,
ﬁbrin isoneofthemostimportant targetsforplasmin in vivo
[100]. The inﬂammatory response initiated by Leishmania
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associated with inﬂammation [101], resulting in the depo-
sition of ﬁbrin matrix within the lesion. This ﬁbrin matrix
would provide, together with other extracellular matrix
proteins, the medium for parasite-macrophage interaction.
Activatedplasminogen ontheparasite surface, oronsecreted
plasminogen-binding proteins, might thus help to degrade
this ﬁbrin matrix favoring the encounter with macrophages.
In the latter case, secreted plasminogen-binding proteins
would act as “torpedo mines” mediating clearance of ﬁbrin.
Indeed, secreted proteins of L. mexicana are able to enhance
the plasminogen activation by t-PA [66]. Macrophages have
also plasminogen receptors [102] and produce plasminogen
activator [103]. The plasmin formed on these cells, together
with metalloproteases, mediate macrophage migration dur-
ing the inﬂammatory process [104, 105]. This relation
plasminogen-Leishmania-macrophage might even be more
complex. It is known that plasmin can have a cytoprotective
eﬀect on macrophages by inhibiting apoptosis in these cells
[106] and could so support more infection by the parasite.
It is clear, however, that more information is needed to
assess the function of the interaction of Leishmania parasites
with plasminogen. Equally, more studies of the role and
dynamics of ﬁbrin in the leishmaniasis lesion are needed as
well as of the eﬀect of this molecule and plasminogen on the
inﬂammation process within the lesion.
Although ﬁbrinolysis seems to be the most important
function of plasmin [100] ,o n em a yn o td i s c a r dt h ep o s s i -
bility that other known functions of this enzyme may play
ar o l ei nt h ec a s eo fLeishmania infection and pathogenesis.
Plasmin can function in procollagenase activation and
release of peptides for nutrition [85]. Since both Leishmania
parasites and macrophages have plasminogen receptors, it is
tempting to speculate that plasminogen might act as a bridge
between these two cells. Moreover, it has been demonstrated
previously that the pathogen Mycoplasma fermentans is
able to adhere and invade HeLa cells in a plasminogen-
dependent manner [107]. Although the real function of
the interaction plasminogen-Leishmania is not known, this
interactionsuggeststhatplasminogen-bindingproteins,such
as enolase, could be virulence factors.
7.Discussionand Conclusions
As described above, enolase may have one or more of
three important functions in the diﬀerent trypanosomatid
parasites, in glycolysis, in gluconeogenesis, and/or as plas-
minogen receptor. In bloodstream-form T. brucei, enolase is
involved in glycolysis, a process crucial for the ATP supply of
the parasites. In intracellular Leishmania amastigotes, amino
sugars are utilized as carbon and energy source, while also
gluconeogenesis is an essential pathway for the synthesis of
glycoconjugates and β-mannan, both required for virulence
of the parasite; therefore, enolase should also be important
for the parasitic life of this organism. Less information exists
about the nature of the carbohydrate and energy metabolism
of the human-pathogenic stages of T. cruzi,b u tt h ea v a i l a b l e
data indicate that axenically cultured trypomastigotes and
amastigotes are highly dependent on glucose catabolism,
strongly suggesting that, also in these cells, enolase fulﬁlls
an essential function in metabolism. Therefore, in each of
these trypanosomatid species, enolase may be considered as
a validated or at least a highly likely candidate drug target.
In addition to this essential metabolic role played by
enolase in the cytosol of the parasites, the enzyme was also
shown to be present, in a catalytically inactive form, at the
outer surface of L. mexicana and T. cruzi (W. Qui˜ nones,
a n dJ .L .C o n c e p c i ´ on, and L. Avilan, unpublished results),
where it probably acts as a plasminogen receptor. Although
pathogens may have also other means to bind plasminogen,
in L. mexicana, enolase was proposed to be the predominant
receptor for this zymogen, responsible for 60% of its total
binding. This plasminogen binding, and the subsequent
activation of the plasminogen into the protease plasmin,
could be important for the parasite’s virulence.
Several moonlighting functions are known for the
glycolytic/gluconeogenic enzyme enolase (discussed in
Section 1). In some cases, organisms have multiple enolase
isoforms, and some moonlighting functions have been
attributed to speciﬁc isoforms. In each of the trypanoso-
matids, except in T. gambiense, only a single enolase gene
copy is present, thus the encoded protein must be respon-
sible for both the glycolytic/gluconeogenic activity and the
plasminogen-binding function. Theabsenceofactivityofthe
surface-associated plasminogen-binding form may be due to
processing of the enzyme during or after its translocation
acrosstheplasmamembrane.Thisremainstobedetermined.
How the enzyme arrives at the surface, and is bound to the
membrane, is not clear yet. The protein does not possess a
predicted transmembrane region or glycosylphosphatidyli-
nositol (GPI) anchor site, nor a detectable N-terminal
transit peptide, suggesting that it is not transported via the
classical secretion pathway. Moreover, enolase was detected
in the secretome of L. donovani [68], and also in that of
T. brucei, both bloodstream-form and procyclic cells [71,
72]. Strong experimental evidence has been provided for
both Leishmania and Trypanosoma that these parasites use
multiple nonclassical secretion pathways, including active
exocytosis via microvesicles or exosomes. This suggests that
the enolase is ﬁrst secreted and subsequently retrieved by
Leishmania to associate in a still unknown manner with its
outer surface.
In addition to a gene coding for a typical enolase,
some trypanosomatids possess genescoding for hypothetical
proteins with regions homologous to those of authentic
enolases. It is unlikely that these proteins, which are usually
considerably longer than typical enolases, possess enolase
activity, because some catalytically important residues seem
to be missing. Their location in the cell and their function—
a receptor function or something diﬀerent—remain to be
determined.
Enolases from a variety of pathogenic organisms have
the ability to bind plasminogen via a C-terminal Lys residue.
However, in S. pneumoniae enolase an internal peptide
located in a loop at the surface of the protein was identiﬁed
as the primary site for interaction with plasminogen [31].
For L. mexicana that, like almost all other trypanosomatid
enolases (except T. congolense), lacks a C-terminal Lys, a
peptide was found with high sequence similarity to, and10 Enzyme Research
at the corresponding position as a plasminogen-binding
peptide of, S. pneumoniae enolase. This sequence is highly
conserved in the enolase of all other Leishmania species.
The plasminogen binding of Leishmania enolase and the
involvement of this peptide in this interaction, remain to be
proved by biochemical and/or structural studies.
The peptide is also well conserved in the enolase of
T. cruzi as well as, intriguingly, in that of all species of
African trypanosomes. The necessity of T. cruzi to recruit
host plasminogen can be understood in view of the fact
that this parasite, like Leishmania spp., invades tissues and
enters cells and may require extracellular proteases for
these activities. However, the conservation of the candidate
zymogen-binding peptide and the presence of enolase in the
secretome of the extracellularly living T. brucei raises the
question as to whether it plays also a role as plasminogen-
receptor in African trypanosomes, and if so, what could be
the function of recruiting a host protease. It should be noted
that, whereas in L. mexicana the enolase is bound to the
cell surface, it has not been detected in the proteome of the
T. brucei plasma membrane [108]. The ability of African
trypanosomes to degrade ﬁbrinogen and ﬁbrin has already
been reported several decades ago [109]. It may be that
the infection is accompanied with an increased synthesis
of ﬁbrinogen by the host and formation of microthrombi
that have to be dealt with by the parasites. Alternatively, the
parasites may recruit plasminogen from the host to enable
them to cross the blood-brain barrier. This crossing is a still
poorly understood process, but may occur in a paracellular
way. In this case, plasmin, as a host-derived protease, can
help to degrade adherens junctions and tight junctions in
the trypanosome-induced blood-brain barrier dysfunction
model as proposed by Grab et al. [110].
T h ef a c t st h a te n o l a s ep l a y sa ne s s e n t i a lf u n c t i o ni nt h e
metabolism of probably all trypanosomatids and is probably
an important virulence factor for, at least, the intracellular
parasites oﬀer two possibilities for using this protein to
combat or prevent an infection. First, the presence of the
plasminogen-receptor form of enolase could be used in two
diﬀerent ways to interfere with the virulence of the parasites.
Compounds may be developed as drugs that prevent or
disrupt the receptor-plasminogen interaction. Alternatively,
the trypanosomatid enolase, or unique parts of its sequence,
may be used either as an antigen for an infected person
to boost his immune system in combating the parasites,
or it may be administered as a vaccine to protect people
at risk of being infected. Secondly, as discussed above, the
availability of the crystal structure of T. brucei enolase has
opened the possibility to design parasite-enzyme selective
inhibitors. Substrate analogues may be synthesized that
exploit unique physicochemical and/or steric features of
the catalytic site of the parasite’s enzyme and, therefore,
providehigh aﬃnityand selectivity.Moreover,incorporating
substitutions that interact with the reactive Lys and Cys
residues (Figure 3) speciﬁc of the trypanosomatid enolases
will not only increase the selectivity but also render the inhi-
bition irreversible. Irreversible and uncompetitive inhibitors
are particularly attractive because, contrary to the much
more often observed competitive inhibition, the increase of
substrate concentration, resulting from this process, will not
overcome the inhibition but may rather lead to an increase
of metabolic intermediates to toxic levels [111]. Because
of the high similarity between the enolases of the diﬀerent
trypanosomatids, it is likely that inhibitors developed in this
way for the T. brucei enzyme may also aﬀect the activity of
the enzymes of T. cruzi and Leishmania spp. Alternatively,
the availability of systems for the easy production of puriﬁed
bacterially expressed enolases of all three trypanosomatids
allows high-throughput screening of large libraries of drug-
like compounds. Any hits obtained by such screenings
will subsequently be optimized through successive cycles
of structure-activity relationship (SAR) analysis. The next
steps in the development of drug candidates against these
diseases will involve the selection of compounds with
potent and highly selective inhibitory activity on cultured
parasites versus human cells, and the evaluation of their
eﬃcacy, bioavailability, and toxicity in infected animal
models. Finally,leadcompoundsthusobtainedmayservefor
their further development to trypanocidal or leishmanicidal
drugs.
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